# Noah AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/noah-ai

- Industry: Healthcare IT
- Headquarters: Beijing, China
- Website: www.noahai.co
- Latest round: Series A (Aug 20, 2025)
- Investors on record: 1

## About

Based in Beijing, China and founded in 2023, Beijing Ruosheng Intelligent Technology Co., Ltd., doing business as Noah AI, is an artificial intelligence pharmaceutical developer that focuses on the development of artificial intelligence (AI) in the medical industry.

In December 2025, Noah AI closed pre-series A+ funding co-led by new investor HSG and returning investor Yijing Investment, with participation from new investors China International Capital Corporation and Sinovation Ventures.

Noah AI specializes in providing analytical tools and real-time monitoring solutions tailored for the pharmaceutical industry. Their core offerings include a platform that tracks the competitive landscape of drug development and analyzes clinical outcomes. Noah AI also facilitates access to up-to-date information from leading medical conferences, including events like ASH and ASCO. The company's products are marketed in North America, Europe, and Asia, catering to a diverse clientele that includes drug developers, investors, and healthcare professionals.

Noah AI generates revenue through subscription-based models for their analytical platform. Clients pay a recurring fee for continuous updates and real-time data analytics on drug development and clinical outcomes. The company also engage in partnerships with pharmaceutical firms to provide tailored solutions that address specific research and development needs.

The pre-series A+ funding will be primarily used by the company for talent recruitment, product development, and business expansion.

## Funding rounds

- Series A, Aug 20, 2025 — Yijing Investment

## Investors

- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series A